Cannassure was granted a patent for an oral delivery method of cannabis and cannabinoids compositions by the Israel Patents Authority
Cannabis Law Report
AUGUST 9, 2021
The patent will be in force until July 14, 2040. Currently the medical cannabis market is based on smoking inflorescence and oil for sub-lingual administration. Cannassure is engaged in the breeding, cultivating, processing, distribution and R&D of medical cannabis products. SOURCE Cannassure Therapeutics Ltd.
98 
Let's personalize your content